Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fluticasone propionate + salmeterol versus placebo for post-transplant FEV1 decline in children
2020-003010-12Phase 3
- Sponsor
- Assistance publique - Hôpitaux de Paris
- Start
- Oct 2020
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Small Molecules
- Countries
- 1
01
Overview
Phase 3 trial of fluticasone propionate and salmeterol in Bronchiolitis Obliterans Syndrome (BOS) (2 arms), sponsored by Assistance publique - Hôpitaux de Paris. Primary endpoint: Change in FEV1 percent predicted.
02
Drugs
fluticasone propionatesalmeterol
03
Conditions
Bronchiolitis Obliterans Syndrome (BOS)
Beyond the preview
Go deeper on 2020-003010-12.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-003010-12.